Latest Manufacturing News

Amaero Ltd has launched a $3 million Share Purchase Plan offering eligible shareholders in Australia and New Zealand the chance to buy new shares at $0.40 each, matching a recent placement price. The offer opens on 29 August and closes on 19 September 2025.

Alpha HPA Limited reported a $32.6 million loss for FY2025 while making significant progress on its HPA First Project Stage 2 and securing $400 million in senior debt financing. The company is capitalizing on growing demand from the semiconductor sector with strong Letters of Intent covering 62% of Stage 2 capacity.

Structural Monitoring Systems plc has reported its first profit after tax, driven by strong avionics sales and a successful $8.7 million capital raise. The company’s strategic shift towards proprietary products and key certifications underpin a positive outlook.

Acrux Ltd reported a 44% revenue decline and a modest increase in net loss for FY25, while expanding its US topical generics portfolio and entering the Saudi Arabian market. The company signals a strategic pivot amid intensifying competition and lower returns.

Australian Dairy Nutritionals Group (ASX, AHF) reported a 14% revenue increase to $7.17 million for FY25, driven by a nearly fourfold surge in its infant formula segment, while reducing its net loss by 29%. The company remains debt-free and is expanding its footprint in China and Vietnam.

Orbital Corporation Limited posted a $4.3 million net loss for FY25, reflecting a revenue decline amid production transitions. The company secured a $3 million capital raise to support new UAV engine development and expand its global footprint.

Metal Powder Works Limited reported a 15% revenue decline and a 224% surge in net loss for FY2025, driven by acquisition costs and a pivot towards long-term contracts.

Jatcorp Limited reported a $6.9 million net loss for FY25, hit by a trademark dispute in China that suspended key product sales. Despite setbacks, the company is accelerating new channel growth and product innovation to regain momentum.

Mesoblast Limited marked a transformative year with FDA approval and commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, driving a 191% jump in cell therapy revenues. The company is now poised to expand its footprint in inflammatory diseases with multiple clinical trials and label extensions underway.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

PPK Group reported a statutory loss in FY25 driven by a significant non-cash impairment of its lithium-sulfur battery investment, while its ballistics division achieved record revenue and battery sales gained momentum from government programs.

PPK Group Limited reported a significant statutory loss for FY25, driven by a major non-cash impairment on its Li-S Energy investment, while its ballistic protection arm Craig International Ballistics delivered exceptional revenue growth.